July 27, 2016 9:02 AM ET


Company Overview of Tranzyme, Inc.

Company Overview

As of July 15, 2013, Tranzyme, Inc. was acquired by Ocera Therapeutics, Inc., in a reverse merger transaction. Tranzyme, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-based therapeutics primarily in the United States. The company’s pre-clinical product pipeline includes TZP-201, a motilin antagonist, for the treatment of various forms of moderate-to-severe diarrhea; and TZP-301, a ghrelin antagonist, for the treatment of metabolic diseases. The company has strategic collaboration with Bristol-Myers Squibb Company to discover, develop, and commercialize additional novel compounds. Tranzyme, Inc. was founded in 1998 and is headquar...

5001 South Miami Boulevard

Suite 300

Durham, NC 27703

United States

Founded in 1998

29 Employees





Key Executives for Tranzyme, Inc.

Tranzyme, Inc. does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Tranzyme, Inc., please visit www.tranzyme.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.